The landscape of employer-sponsored healthcare benefits in the United States is bracing for a significant financial shock, with costs projected to escalate by nearly 10% in 2027. This alarming forecast comes from the latest annual survey conducted by the Business Group on Health (BGH), a leading organization representing large U.S. employers. Executives from BGH have characterized the current environment as "unprecedented," underscoring the immense pressures confronting employee benefits teams nationwide. This anticipated surge marks a critical juncture for businesses striving to balance comprehensive employee care with sustainable financial models.
A Persistent Trend: Exceeding Projections Year After Year
The 2027 projection is not an isolated incident but rather the culmination of a worrying trend. The year 2025 marked the third consecutive year in which actual healthcare expenditures surpassed the initial projections made by BGH member companies. This consistent underestimation highlights a systemic challenge in forecasting and managing healthcare costs within the corporate sector. The data from the 2025 period revealed an 8.8% year-over-year increase, an unprecedented figure representing the highest surge ever reported by BGH members. The survey encompassed insights from 127 large U.S. employers, collectively representing a vast network of 8.7 million covered individuals, providing a robust snapshot of the national employer-sponsored health benefits market.
"It’s clear that employers are at an inflection point," stated Brenna Shebel, Vice President at BGH, during a press conference held on Tuesday to announce the survey results. This sentiment resonates deeply within the industry, as companies grapple with the dual challenges of maintaining competitive benefits to attract and retain talent while simultaneously facing relentless cost escalation. The consistent pattern of actual costs outstripping projections suggests that traditional cost-containment strategies may no longer be sufficient in the rapidly evolving healthcare ecosystem.
The Anatomy of Rising Costs: Key Drivers Identified
The BGH survey meticulously identified the primary drivers behind this projected cost acceleration, pointing to a combination of persistent disease burdens, escalating facility charges, and the spiraling expense of pharmaceuticals. These factors collectively contribute to a complex financial challenge for employers.
Disease Burden
Consistent with findings from previous editions of the survey, specific disease categories continue to exert immense pressure on healthcare budgets. Cancer, musculoskeletal disorders, and cardiovascular diseases were cited as the predominant drivers of the cost trend. The reasons behind the high costs associated with these conditions are multifaceted. Cancer treatments, for instance, often involve highly advanced, expensive therapies, including novel immunotherapies, targeted drugs, and complex surgical procedures, alongside long-term supportive care. Musculoskeletal conditions, such as chronic back pain, arthritis, and sports injuries, frequently require extensive physical therapy, specialized consultations, imaging, and sometimes costly surgical interventions like joint replacements. Cardiovascular diseases, similarly, necessitate ongoing management with expensive medications, diagnostic tests, interventional procedures, and potential surgeries, often spanning many years. The increasing prevalence of these chronic conditions within the workforce further exacerbates their financial impact.
Soaring Facility and Pharmacy Expenses
Beyond specific disease categories, the fundamental cost structures of the healthcare system itself are contributing significantly to the upward trend. Increased prices for hospital services, outpatient facilities, and pharmaceuticals are major contributors. Hospitals, facing their own pressures from labor shortages, supply chain disruptions, and technological advancements, have continued to raise charges. Outpatient facilities, often seen as a more cost-effective alternative to inpatient care, are also experiencing price hikes due reflecting increased demand and operational expenses.
Pharmacy costs, in particular, stand out as a critical area of concern. The BGH survey projects that pharmacy expenditures alone are expected to surge by an astounding 12% in 2027, even before any adjustments or changes in plan design are implemented. This steep increase is largely attributable to the rising cost of specialty drugs, which target complex and rare conditions but come with exorbitant price tags. New drug approvals, often priced at premium levels, and the overall inflationary pressures within the pharmaceutical supply chain further compound this challenge. The role of Pharmacy Benefit Managers (PBMs) in drug pricing and supply chain management also remains a contentious issue, with growing calls for greater transparency in their practices.
Ellen Kelsay, President and CEO of BGH, acknowledged the gravity of these findings, describing the cost-increase projections as "no doubt quite astounding." She further emphasized the challenging timing, noting that most employers have already finalized their employee benefits budgets for 2026. This pre-commitment means that many organizations will be unable to implement drastic cost-cutting measures until 2028 at the earliest, leaving them with limited immediate flexibility to mitigate the impending financial burden.
Navigating the Challenge: Employer Strategies for Cost Mitigation
Faced with these daunting projections, U.S. employers are actively exploring and implementing a range of strategies to rein in escalating healthcare costs. The response is multifaceted, focusing on increased scrutiny of existing partnerships, greater transparency, and the adoption of innovative care models.
Scrutinizing Vendor Partnerships
A significant immediate focus for many employers is a comprehensive review of their vendor relationships and third-party partnerships. The survey revealed that a vast majority of respondents, 95%, have issued requests for proposals (RFPs) or requests for information (RFIs) to evaluate existing and potential partners. Furthermore, 58% of employers indicated plans to replace underperforming vendors or eliminate programs that demonstrate low utilization rates. This signals a proactive approach to optimize the value derived from their healthcare ecosystem. Additionally, 83% of respondents have increased the scope of their performance guarantees from health partners, demanding greater accountability and measurable outcomes from service providers. This strategic shift underscores a move away from passive acceptance of vendor services towards a more demanding, performance-driven partnership model.
The Push for PBM Transparency
Pharmacy Benefit Managers (PBMs), long considered an "oft-maligned player in the healthcare space" due to concerns over opaque pricing practices and rebate structures, are facing intensified scrutiny. The BGH survey highlights a significant shift towards greater transparency in PBM arrangements. Nearly one-third of BGH respondents indicated that they would have a "transparent" or "new-generation" PBM arrangement in place by 2027. An additional 47% of employers were actively considering making such a transition in future years.
Transitioning to a new PBM model, however, is a complex and time-consuming process. Kelsay noted that these transitions typically take an average of 12 to 18 months, as employers need to conduct thorough due diligence to ensure a smooth and effective shift to a new partner. "These are big, big processes for employers," Kelsay explained. "It’s not something they can quickly turn on a dime." This reflects the intricate nature of healthcare benefit management and the significant internal resources required for such strategic overhauls. The move towards transparent PBMs aims to provide employers with clearer insights into drug pricing, rebates, and administrative fees, ultimately seeking to reduce costs and improve overall plan efficiency.
Embracing Innovation: Non-Traditional Care Models Gain Traction
Beyond vendor management, employers are increasingly turning to non-traditional and emerging care models to enhance quality, improve outcomes, and control costs. These innovative approaches represent a paradigm shift from traditional fee-for-service models towards more integrated, value-driven care.
Centers of Excellence and Value-Based Care
One prominent strategy gaining traction is the utilization of Centers of Excellence (COEs). COEs are specialized healthcare facilities or programs recognized for delivering high-quality, cost-effective care for specific complex medical conditions, such as organ transplants, certain cancers, or orthopedic surgeries. By directing plan enrollees to these pre-vetted, high-performing institutions, employers aim to improve patient outcomes, reduce complications, and ultimately lower overall costs by avoiding unnecessary procedures or readmissions. The survey found that 82% of BGH respondents already had a COE model in place in the current year, with an additional 12% either adding or considering this option moving forward. This widespread adoption underscores the perceived value of COEs in optimizing care delivery.
Furthermore, value-based solutions, high-performance networks, and accountable care organizations (ACOs) are also gaining momentum. Value-based care models tie provider reimbursement to patient health outcomes and quality of care, rather than simply the volume of services provided. High-performance networks involve carefully selected groups of providers who meet specific quality and efficiency criteria, offering employers and employees access to high-value care. ACOs are groups of doctors, hospitals, and other healthcare providers who come together voluntarily to give coordinated high-quality care to their Medicare patients, and increasingly, to commercially insured populations. The goal of these models is to foster collaboration among providers, improve care coordination, prevent chronic disease progression, and ultimately reduce overall healthcare spending.
The GLP-1 Conundrum: Employers Rethink Weight Management Coverage
While employers are exploring various avenues for cost containment and care improvement, one specific area has seen a notable pullback: coverage for GLP-1 (glucagon-like peptide-1) medications, particularly when prescribed for weight management. These drugs, known for their efficacy in managing blood sugar for diabetes and promoting significant weight loss, have become a major point of discussion due to their high cost and increasing demand.
The Financial Weight of GLP-1s
The BGH survey revealed a stark shift in employer attitudes towards GLP-1 coverage for weight management. Not a single employer surveyed indicated plans to add GLP-1 coverage for weight management in 2027. More strikingly, 14% of respondents stated they have already dropped or plan to drop this coverage by 2027. Even among the 60% of BGH members who plan to maintain GLP-1 coverage for weight management, a significant caveat applies: they largely intend to implement stronger utilization controls. These controls include stringent clinical eligibility criteria, requiring patients to meet specific health markers, and mandating participation in comprehensive weight management programs that may include dietary counseling, exercise regimens, and behavioral therapy.
The primary driver behind this recalibration is the immense expense associated with GLP-1 drugs. These medications can cost thousands of dollars per month per patient, posing a substantial financial burden on employer-sponsored health plans, especially as their popularity for weight loss skyrockets. The rapid expansion of the direct-to-consumer market for GLP-1s has also complicated matters, leading to increased demand and challenges in managing appropriate utilization within employer plans.
Re-evaluating Comprehensive Obesity Management
Kelsay articulated that part of the employer’s dilemma with GLP-1s stems from their emerging role as a default option for weight loss, rather than being integrated as one of many available pathways for patients. She emphasized the importance of reframing the conversation to include other long-standing and often more holistic programs that employers have historically offered. This includes other anti-obesity medications, lifestyle and behavioral modification programs, nutrition counseling, and bariatric surgery options.
This perspective is reinforced by external data, such as this year’s SHRM Employee Benefits Survey, which similarly found a significant disparity in GLP-1 coverage. The SHRM survey indicated that coverage for GLP-1s for diabetes management far outpaced coverage for weight management, reflecting a broader trend of employers prioritizing clinically established and often more cost-effective treatments for severe conditions. "For many employers, they’re having to make some hard decisions about maintaining the viability of their overall plan and whether or not they can do so while still continuing GLP-1s," Kelsay stated. This decision-making process involves a careful assessment of the budget, the clinical appropriateness of the drugs, and the availability of alternative, comprehensive obesity management solutions.
Broader Implications: The Future of Employer-Sponsored Health Benefits
The projected near 10% increase in healthcare costs for U.S. employers in 2027 carries profound implications that extend beyond the balance sheets of corporations. This financial pressure will inevitably influence the design, scope, and accessibility of employer-sponsored health benefits, potentially affecting millions of American workers and their families.
The sustained upward trajectory of healthcare costs challenges the fundamental viability of current benefit structures. Employers are under increasing pressure to find sustainable solutions, which could manifest in various ways:
- Increased Employee Cost-Sharing: To offset rising plan costs, employers may be compelled to pass on a greater portion of expenses to employees through higher premiums, deductibles, co-pays, and out-of-pocket maximums. This could place a significant financial strain on workers, especially those with chronic conditions or lower incomes.
- Reduced Benefit Offerings: Some employers might consider paring back certain benefits or limiting coverage for specific services or medications, as seen with the evolving stance on GLP-1s for weight management. This could lead to a less comprehensive benefits package overall.
- Innovation in Plan Design: The intensified focus on COEs, value-based care, and high-performance networks suggests a long-term commitment to optimizing care delivery and seeking greater efficiency. This could lead to more tailored and integrated care pathways for employees.
- Enhanced Wellness and Prevention Programs: As costs for treating chronic diseases rise, employers may further invest in preventive care and wellness programs aimed at improving overall employee health, thereby reducing the incidence and severity of costly conditions.
On a macro level, the consistent escalation of employer healthcare costs contributes to the broader national dialogue on healthcare affordability and accessibility. While employer-sponsored plans remain the primary source of health insurance for many Americans, their financial sustainability is increasingly under question. Policy discussions at state and federal levels concerning drug pricing, hospital transparency, and the role of PBMs are likely to intensify in response to these persistent cost pressures. The BGH survey serves as a stark reminder that without systemic changes and innovative approaches, the financial burden of healthcare will continue to mount, presenting a formidable challenge for businesses, employees, and the nation’s economy alike. The "inflection point" described by BGH executives suggests that the decisions made by employers in the coming years will shape the future landscape of American healthcare.
